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Abstract: Background: The management of esophageal carcinoma is changing but before the introduction of 
chemotherapy and multidisciplinary teams, surgery became more selective. The aim of this study was to confirm this 
trend and to examine survival in a total population cohort 1985-94. 
Results: Only a quarter of 413 patients had surgery but from 1989 even fewer were operated on but there were more long-
term survivors: 1/51 v. 7/58 (p<0.05). Operative mortality fell from 12% to 6.9 % in the later period (N.S.) and survival 
post surgery was marginally improved, 15 v. 11 months p = 0.0502. The five year survival rate doubled from 7.8% to 
17.2%. 
Conclusion: Few studies of esophageal cancer include all cases in a defined population. This carries a very poor prognosis 
but the present cohort shows a slight improvement with more selective surgery and this may serve as a benchmark against 
which modern multidisciplinary management might be compared.  
Keywords: Esophageal cancer, Esophagectomy, Radiotherapy, Mortality, Prognosis. 
INTRODUCTION 
 In contrast to the incidence of gastric cancer, which has 
fallen worldwide, the incidence of esophageal cancer has 
been increasing at an appreciable rate. There has been an 
increase in the incidence of adenocarcinoma of the distal 
esophagus, together with a shift of gastric carcinoma from 
the distal part of the stomach to the cardia and esophago-
gastric junction [1-4]. Surgical resection is still the 
treatment for esophageal carcinoma which gives the best 
chance of achieving a cure, but this can only be achieved 
by accurate staging of the disease and may be improved by 
neo-adjuvant or adjuvant chemo-radiotherapy [2, 3]. The 
majority of patients diagnosed with upper gastrointestinal 
cancer only survive a few months after diagnosis because 
of the insidious nature of the condition but this poor 
prognosis is not fully reflected in published series of cases 
referred for surgery. The relatively low incidence of the 
disease in the UK may also delay presentation and result in 
the disease being too advanced at presentation for surgical 
intervention. There was an apparent change in the 
management of esophageal carcinoma with a more 
selective approach to surgical resection and an increase in 
palliation by intubation and radiotherapy in the era before 
the introduction of modern multidisciplinary management  
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[5] with intensive staging investigations and the increasing use 
of chemotherapy. However the evidence for such a trend has 
been anecdotal and any change in practice and outcome has 
not been well documented. A ten year cohort study spanning 
the period of the perceived change of management, 1985-
1994, was therefore carried out. The inclusion of all cases of 
esophageal cancer in a defined population documents the 
overall survival from the disease in the era preceding current 
multidisciplinary management.  
MATERIALS AND METHODS 
 Over a ten year period between 1985-1994, all cases of 
esophageal carcinoma were studied in a Health District with a 
stable population of approximately 280,000. All death 
certificates over the period were examined and a computer 
search of the histopathological data-base was carried out for all 
cancers of the esophagus and stomach. A hand search was 
made of the operating theatre logbooks and a hand/computer 
search of the endoscopy records was also performed. Where 
possible the hospital records were retrieved and those cases of 
documented carcinoma of the cardia were included. Details of 
the histological type and node status were recorded. Cases 
with carcinoma of the body and distal stomach were excluded. 
 Details of the type of stent inserted and whether the latter 
was used in conjunction with chemo- or radiotherapy were 
recorded. The type of surgical resection and the operating 
surgeon were recorded. Data on the trends in the catchment 
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population over the period of the study were obtained from 
the Office for National Statistics [6]. The treatment year 
and the length of survival were taken from the date of 
diagnosis. Operative mortality at 30 days was taken from 
the date of operation. All patients were followed up and at 
the most recent review of the survivors in October 2005, 
the minimum length of follow-up was 11 years. Overall 
and recurrence-free survival following primary treatment 
with surgery, radiotherapy alone, dilatation/intubation 
alone or supportive care were compared by Life Table 
analysis (Kaplan-Meier) and statistical analysis by the log 
rank test (Medcalc Schoonjans 2005). 
RESULTS  
 A total of 413 patients diagnosed with esophageal 
carcinoma was identified between 1985 and 1994 of whom 
109 had a surgical resection. From 1992 onwards there was 
a sharp decline in the proportion of patients treated by 
surgery, (Fig. 1) although the number of cases increased 
(Table 1). In the last 2 years of the study only 9 of 84 
(11%) patients with esophageal cancer had a surgical 
resection. 
 There was a corresponding rise in the proportion of 
patients treated conservatively from 63% up to the end of 
1988, to 79% in the subsequent years. The proportion of 
patients who received radiotherapy with palliative intent 
(n=92), or in addition to surgery (n=14) also rose over the 10 
year period (Fig. 1). 
ESOPHAGEAL DILATATION/INTUBATION 
 Dilatation of esophageal cancers with or without intubation 
was carried out in 234 patients (Table 1) and in 103 cases this 
was the sole primary treatment. Palliation with a stent was 
attempted in 93 patients of which 73% were of Celestin type, 
22% Nottingham/Atkinson and 5% were not recorded. No 
patient in this cohort received intubation with an expandable 
metal stent. 
CHEMOTHERAPY 
 Chemotherapy was only given to 13 patients which was 
adjuvant to other treatment in 9 patients but in 4 was the sole 
primary treatment. 
SUPPORTIVE CARE 
 No active primary treatment was given to 105 patients 
(25%) who received supportive care. This group included 12 
patients where the diagnosis was only confirmed at post 
Table 1. Treatments Received by all Patients by Year 1985-1994: Treatment given to Total Cohort 
 
 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 Total 
Chemotherapy 2 1 0 1 0 1 2 2 3 1 131 
Radiotherapy 6 8 6 6 13 11 12 13 14 17 1062 
Stenting/dilatation 19 22 33 19 26 21 20 22 20 32 2343 
Supportive care only 8 5 7 7 17 14 9 15 13 10 1054 
Surgery 10  10 14 18 9 14 14 11 6 3 109 
TOTAL 33 31 40 36 51 48 38 52 45 39 413 
Notes: 1Chemotherapy was usually given in combination but in 4 cases this was the sole treatment; 2Radiotherapy was the primary palliative treatment in 92 cases: in 14 it was 
given in combination with surgery; 3Stents were used in 83 cases. Dilatation + intubation was the sole 1o treatment in 103 cases; 4The supportive care group include 12 patients 
where diagnosis was confirmed at postmortem and 37 patients where the diagnosis was established but no specific 1o therapy was given. 
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mortem and 37 patients where the diagnosis was confirmed 
but no definitive treatment was given. 
SURGICAL RESECTION 
 Of the 109 patients treated by surgical resection, under 
the care of four surgeons, 59% underwent transhiatal 
esophagectomy, 16% an Ivor-Lewis operation, 12% a left 
thoracic approach, 7% a transabdominal operation for 
carcinoma of the cardia and in 4% a 3 stage procedure was 
carried out. In 3 cases the operation record was not 
available. Adjuvant radiotherapy was given in 14 surgical 
cases and chemotherapy in 5.  
PATHOLOGY 
 Histological confirmation was confirmed in 93% of cases. 
In the first two years 1985-1986 the incidence of 
adenocarcinoma (47%) was similar to squamous cell carci-
noma but thereafter adenocarcinoma became predominant 
(70%). 
PREOPERATIVE STAGING 
 CT scans were not available until the last three years of the 
study but pre-operative staging by laparoscopy was used to an 
increasing extent in the later years. 
 
Fig. (2). Survival of operated patients by node status. 
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POPULATION ESTIMATE 
 The office for National Statistics estimated the rise in 
the catchment population for S.E. Kent over the study 
period in the age range 70-74 to have been 7% in males 
and 4.8 % in females [6]. It is unlikely that many patients 
were referred outside the district for the treatment of 
esophageal cancer over the period of the study. Only one 
patient is known to have been referred for resectional 
surgery in London. 
SURVIVAL  
Node Status 
 Of 109 patients who had a surgical resection the nodes 
were positive in 69 (63%), negative in 36 and not recorded 
in four. The median survival in the node negative patients 
was 24 months compared with 11 months for the node 
positive patients (p<0.001) (Fig. 2). 
 The median survival of 109 surgical patients was 12 
months, compared with 6 months for the 92 patients treated 
by palliative radiotherapy. The median survival for the 
group treated primarily with dilatation/intubation was 3.5 
months and for those who received supportive care 1.5 
months (Fig. 3). 
 The median survival of the operated patients who had 
adjuvant radiotherapy (n=14) was 29 months compared 
with 12 months for those who did not (n=95) but the 
difference was not significant. (p= 0.22) The median 
survival of the 13 patients who had chemotherapy was 13 
months. Only 15 squamous carcinomas were resected with 
a median survival of 12 months. 
 There were more long-term survivors in the later period 
1989-94 (7/58) vs 1/51 in the earlier 4 years (p<0.05. 
Fisher’s exact test), when the proportion of surgical 
treatment for esophageal cancer was in decline. There was 
no difference in the overall median survival with the apparent 
change in the management 1985/88 v. 1989/94. Hazard ratio 
0.95 (95% CI = 0.76 to 1.155) (Fig. 4). 
 However, there was a marginal improvement in survival 
seen in the surgical patients operated on in the later period. 
The five-year survival rate doubled from 8% to 17.2% and the 
median survival of 15 months compared with 11 months in the 
early group 1985/88 p= 0.0502 Hazard ratio 1.46 (95%CI 
0.9997 to 2.26) (Fig. 5). 
 There were 10 post-operative deaths within 30 days (9.3%) 
but the operative mortality in the early period 1985/88 fell 
from 6/51 (12%) to 4/58 (6.9%) in the later period. (N.S.) The 
five year survival rate of the operated patients including post-
operative mortality was 12% (13/109). 
 There were only 8 long-term survivors at 10 years post 
surgery (7.3%), none of whom had received adjuvant 
chemotherapy or radiotherapy. One patient was lost to follow-
up at 33 months post surgical resection, when clinically free of 
recurrence. Of the long-term survivors three had a squamous 
carcinoma and five an adenocar-cinoma. Five patients treated 
by surgery between 1989 and 1994 were still alive in October 
2005 but all non-surgical patients had died. 
DISCUSSION 
 The very few long-term survivors in this total population 
cohort of patients from the decade 1985-1994 had all been 
treated by surgery alone. The increasing place of 
chemotherapy in the treatment of esophageal cancer had not 
yet been established but his study does document a change in 
practice towards a more selective management of esophageal 
cancer with a decline in the rate of surgical resection. The 
outlook for those patients offered surgery improved and it is 
likely that the reduction of operative mortality from 12% to 
6.9% is largely due to improved intensive care facilities. 
However, the separation of the survival curves at about 1 year 
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in Fig. (5), in the absence of adjuvant therapy in the long-
term survivors suggests that case selection may have 
improved. CT scans were only available from 1992 and 
pre-operative staging by laparoscopy was used to an 
increasing extent in the latter part of the study. It is likely 
that these two factors largely account for the reduced 
number of patients offered surgery towards the end of the 
period (Fig. 1). Every effort was made to identify all cases 
of esophageal cancer in the defined population cohort and 
although it is possible that more patients were referred to 
specialist centers this was not common practice over this 
period and any such case is likely to have been identified 
by the pre-operative biopsy or the death certificate. The 
few cases diagnosed at post mortem, where this was the 
certified cause of death, are unlikely to have died from 
another cause. 
Esophageal Carcinoma in 1985 was the Ninth Most 
Common Malignancy  
 Worldwide [5] and the incidence in England and Wales 
continues to rise. A number of factors have been attributed 
to this increase in incidence, which include alcohol, 
smoking, obesity, an increase in Barrett’s oesophagus 
secondary to reflux disease and the introduction of H2 
blockers [1,2,7,8]. A number of potentially curative and 
palliative treatments exist and although surgical resection 
has remained the main chance of cure for this condition, 
treatment has latterly been reinforced by adjuvant 
chemoradiotherapy [9-12] and most recently with evidence 
of survival benefit from perioperative chemotherapy [13]. 
There is now evidence that a high surgical workload 
improves operative mortality but this is as much a factor of 
the hospital volume as of the surgeon [14-16] and in the 
UK this has lead to regionalization of high risk gastrointes-
tinal surgery.  
 A transthoracic three-field lymphadenectomy carries 
considerable morbidity and since node positive disease has 
such a poor prognosis, considerable efforts are now made to 
exclude local extension and node involvement with 
endoluminal ultrasound [17, 18] and more distant disease with 
a CT-PET scan [19]. The transhiatal operation has much the 
same long-term outcome and since this approach carries less 
morbidity than the transthoracic operation this may have some 
advantage [20]. 
 Palliative procedures carry their own morbidity and 
mortality so that quality of life assessment is most important. 
Blazeby et al. have shown that patients treated with palliation 
alone have consistently poorer function and more troublesome 
symptoms [21] but quality of life scores may not predict short-
term outcome [22]. Esophagectomy does not always give good 
palliation especially when the mean survival was only 12 
months but quality of life data were not available for the 
current cohort of patients. 
 The present study confirms that there was a definite change 
in management of esophageal cancer with fewer surgical 
resections and an increase in palliative treatment over the ten 
year period 1985-94. Palliation mainly took the form of 
intubation with the previous generation of rigid plastic tubes 
[23] or radiotherapy and very few patients received 
chemotherapy. There was no change in consultant medical or 
surgical staff over the study period but although they did not 
function as a multidisciplinary team at this time, a gradual 
change in practice has been confirmed.  
 Over the ten year period of study both the male and female 
population increased by 7.3% and 4.8% respectively for 70-74 
year age group which would indicate that there were more 
people at risk of developing esophageal carcinoma in the latter 
part of the study. One would therefore have expected to see an 
increase in the number of patients having surgery but this was 
not the case.  
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 The reported operative mortality and 5 year survival of 
esophagectomy vary widely but the nearest series to the 
present study is a Finnish cancer registry based population 
cohort of 402 patients with adenocarcinoma diagnosed 
between 1990 and 1998 [24]. The operation rate of 42.5% 
was higher than the rate of 27% in the present series and 
although the operative mortality was similar at 8.8% the 5 
year survival was higher at 29% v. 12%. The operative 
mortality of transhiatal esophagectomy within the present 
study was 5.9% [25]. 
 Thirty day operative mortality as low as 1.1 % has been 
reported from France [26] with a 5 year survival of 59%. 
However, this was a series with 78% squamous carcinoma 
and only 29% node positive cases. The present study more 
closely matches the data from Southampton [27] and 
Australia [28]. In the former study, for 1974-1996 the in-
hospital mortality fell from 8.8% to less than 5% but the 5 
year survival remained disappointingly low at 15.3% 
compared with 17% in the latter part of the present study.  
 The trend towards more careful selection of patients for 
surgery has not been the result of randomised controlled 
trials or prospective studies but reflects a change of 
practice in the light of a poor outcome for many patients 
[29, 30]. The short median survival of 11 months for node 
positive patients who had a surgical resection underlines 
the need to identify this group as far as possible by 
imaging techniques before surgery is considered. It is clear 
that the multidisciplinary team approach has further 
improved the staging accuracy and care of esophageal 
cancer [31, 32] and there is some evidence from historical 
controls that it has improved outcome [33, 34]. Modern 
therapy has substantially improved the outcome for 
operable esophageal cancer but the present study may 
serve as a benchmark when all cases presenting in a 
defined population are considered.  
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